08:00 , Nov 15, 2010 |  BioCentury  |  Strategy

Innovators pick China

Five years after he co-founded BioDuro LLC , a contract research organization operating in China, John Oyler is at it again. But this time, his new team is doing what would have been almost unthinkable...
08:00 , Feb 21, 2008 |  BC Innovations  |  Targets & Mechanisms

Hitting pain where it hurts

The molecular mechanisms of neuropathic pain are not well understood, and existing treatments typically provide only temporary relief-often with significant side effects-by blocking pain signaling instead of stopping pain at the source. Now, Boston-area researchers...
01:18 , Feb 17, 2007 |  BC Extra  |  Clinical News

Scientists publish mechanism for Shigella infection

Researchers from Beijing's National Institute of Biological Sciences published a study in Science that shows Shigella, a causative agent of dysentery, secretes OspF effector protein into host cells to deactivate p38 mitogen-activated protein (MAP) kinase,...
07:00 , Sep 11, 2006 |  BioCentury  |  Tools & Techniques

Blocking beta cell destruction

Neural cell adhesion molecule (NCAM) , a glycoprotein that is expressed in all nerve cells and has a role in their health, growth and communication, may also be a potential therapeutic target for Type I...
00:53 , Aug 19, 2006 |  BC Extra  |  Clinical News

Researchers publish skin test for AD

Researchers from Blanchette Rockefeller Neurosciences Institute published in the Proceedings of the National Academy of Sciences that an assay comparing the phosphorylation of MAP kinases ERK-1 and ERK-2 in skin fibroblasts can diagnose early Alzheimer's...
07:00 , Jul 3, 2006 |  BioCentury  |  Product Development

Asthma roadMAP

deCode genetics Inc. says population genetics work showing that MAP kinase is an important factor in asthma enabled the company to repurpose a failed Parkinson's disease product from Cephalon Inc. DCGN reported positive data on...
08:00 , Feb 6, 2006 |  BioCentury  |  Product Development

Breathless opportunities

Treatment of asthma has remained essentially unchanged for years and focuses on alleviating symptoms rather than disease modification. In large part, the state of the art reflects inertia on the part of the dominant big...
08:00 , Mar 15, 2004 |  BioCentury  |  Product Development

Small molecule chases TNF

For chronic diseases such as rheumatoid arthritis, it obviously would be preferable to have oral small molecules than injected macromolecules. Last week, A-Viral ASA announced the start of a Phase II trial of its AV1101...